复合GLP-1和双GIP/GLP-1受体激动剂:美国糖尿病协会的一份声明
Joshua J Neumiller1, Mandeep Bajaj2, Raveendhara R Bannuru3
1Department of Pharmacotherapy, Washington State University, Spokane, WA.
Diabetes care
|December 2, 2024
概括
葡萄糖类1受体激动剂 (GLP-1 RA) 和双GIP/GLP-1RA正面临短缺,导致复合版本的安全性问题. 该声明指导安全使用这些重要的糖尿病和肥胖药物.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
背景情况:
- 葡萄糖类1受体激动剂 (GLP-1 RA) 和双糖依赖性胰岛素变型多 (GIP) 和GLP-1 RA (GIP/GLP-1 RA) 药物越来越多地用于2型糖尿病和肥胖症.
- 需求的大幅增加导致这些关键药物疗法的暂时短缺.
- 产品短缺促使复合配方在市场上销售,引发了关于安全性,质量和有效性的重大担忧.
研究的目的:
- 为医疗保健专业人员和糖尿病和/或肥胖患者提供关于药物不可用性的指导.
- 在GLP-1 RA和GIP/GLP-1 RA疗法短缺期间,促进最佳的患者护理和安全的药物使用.
- 解决尽管存在潜在风险,但复合配方的持续营销问题.
主要方法:
- 这是美国糖尿病协会的一份声明.
- 该声明综合了关于GLP-1 RA和GIP/GLP-1 RA疗法,短缺和复合产品的当前信息.
- 它提供了导航药物不可用性和确保患者安全的建议.
主要成果:
- 由于需求高,GLP-1 RA和GIP/GLP-1 RA药物的短缺已经发生.
- 复合配方正在市场上销售,对患者的安全,质量和治疗疗效构成潜在风险.
- 这些复合产品继续被推广,即使短缺可能会解决.
结论:
- 医疗保健专业人员和患者需要明确的指导来管理GLP-1 RA和GIP/GLP-1 RA药物的短缺.
- 在考虑替代疗法或复合疗法时,优先考虑安全性,质量和疗效至关重要.
- 美国糖尿病协会旨在支持为最佳糖尿病和肥胖管理提供知情决策.
相关概念视频
Glucagon-like Receptor Agonists
298
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
298
Dipeptidyl Peptidase 4 Inhibitors
171
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171
Oral Hypoglycemic Agents: Glinides
139
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
139
Oral Hypoglycemic Agents: Biguanides and Glitazones
172
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
172
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
159
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
159
Oral Hypoglycemic Agents: Sulfonylureas
187
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
187


